CHICAGO — The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.
Based on the buzz it created among ASCO Annual Meeting attendees, the benefits observed with daraxonrasib among pretreated individuals with metastatic disease exceeded already-lofty expectations.
Gastrointestinal cancer specialists used words like “unprecedented” and “transformational” to describe the detailed findings from the randomized phase 3 RASolute 302 trial, which establish daraxonrasib (RMC-6236, Revolution Medicines) as the new standard of care for patients with

CHICAGO — The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with localized high-risk prostate cancer, according to findings presented in ASCO Annual Meeting’s plenary session.
Men who received apalutamide (Erleada, Johnson & Johnson) and ADT in the neoadjuvant and adjuvant settings survived longer without recurrence or metastases than those who received placebo plus ADT, results of the randomized phase 3 PROTEUS study showed.
They also more often achieved pathologic response in the prostate.
“The fact that both of our coprimary

CHICAGO — A whole-food plant-based diet can significantly increase weight loss for men with prostate cancer and overweight or obesity who are receiving androgen deprivation therapy.
Data from a randomized trial, presented at ASCO Annual Meeting, showed men who received the dietary intervention and coaching lost approximately 8 pounds more over 6 months than those who received counseling alone. They also had significant improvements in BMI, total mass and fat mass.
“It’s hard to lose weight. For this patient population on therapy, it’s very hard to lose weight,” David M. Nanus, MD, interim chief